Wednesday, 14 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 28, 2026

Adobe’s AI growth takes center stage after guidance raise

View original at finance.yahoo.com
Adobe’s AI growth takes center stage after guidance raise This quarter made one thing clear. Adobe’s (ADBE) AI story now has real revenue behind it…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Management pointed to solid retention, upsell, and paid conversion trends across Creative Cloud and Document Cloud

    60% confidence

  • Adobe faces weaker-than-expected net new ARR and pressure on pricing as freemium AI tools expand usage but weigh on ARPU

    60% confidence

  • Investors will likely focus on whether incoming leadership maintains balance between disciplined execution and aggressive AI investment

    60% confidence

  • The next era of creativity is being written right now, suggesting new leadership is needed to guide that next chapter

    60% confidence

  • The CEO transition is a natural handoff after nearly two decades, framed as entering a new era of creativity being written right now

    60% confidence

  • Adobe faces pressure on high-end users and has limited exposure to lower-priced tiers where demand is growing faster

    60% confidence

  • Adobe's business remains stable but faces concerns around pricing power, competitive pressure, and CEO transition uncertainty

    60% confidence

Data points we hold from this source

Adobe Inc. · enterprise value97.1 USD
Adobe Inc. · forward pe ratio10.0 ratio
Adobe Inc. · ytd stock performance-37 percent
Adobe Inc. · analyst avg price target328.19 USD
Adobe Inc. · ai arr125 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Adobe’s AI growth takes center stage after guidance raise — Source | Via News | ViaNews EU